Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
... (NCI Grades 3/4) lab abnormalities-including
neutropenia (3.6%-48%), anemia (1%-42%), thrombocytopenia ... included anemia (17%), thrombocytopenia (17%),
neutropenia (8%), and increased creatinine (8%).
In ... abnormalities (400 mg/day; 600 mg/day)--including
neutropenia (10%; 11%), anemia (3%; 9%), thrombocytopenia ...
Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer
... toxicities and infections, including:
-
neutropenia - 66% (Grade 3/4 57%) versus 65% (Grade 3/4 59%), with
febrile
neutropenia reported in 7% versus 6% of patients
- ... neutrophil count, hemoglobin level, or
neutropenia with fever) may require dose reduction, delay in
...
Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma
... (each 20%), rash (18%), arthralgia (17%),
neutropenia and dizziness (excluding vertigo) (each 17%), ... toxicity, most commonly thrombocytopenia (5%) and
neutropenia (3%). A total of 50% of patients experienced ... respectively, were thrombocytopenia (52% vs 47%),
neutropenia (49% vs 46%), nausea (48% vs 28%), peripheral ...
Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
... adverse reactions were thrombocytopenia (28%),
neutropenia (28%), elevated lipase (15%), and hyperglycemia ... adverse reactions were thrombocytopenia (37%),
neutropenia (37%), anemia (23%), and elevated lipase (17%). ... (NCI Grades 3/4) lab abnormalities -- including
neutropenia (3.6%-48%), anemia (1%-42%), thrombocytopenia ( ...
Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients
... (each 20%), rash (18%), arthralgia (17%),
neutropenia and dizziness
(excluding vertigo) (each 17%), ... most commonly thrombocytopenia (5%) and
neutropenia (3%). A total of
50% of patients experienced ... were thrombocytopenia (52% vs 47%),
neutropenia (49% vs 46%),
nausea (48% vs 28%), peripheral ...
CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors
... and adverse events were combined, Grade 3 or 4
neutropenia occurred in 8% and Grade 3 or 4 platelet ... 9.5% of patients over age 70 experienced Grade 4
neutropenia or thrombocytopenia in the first cycle, ... equal to age 70, 7% and 5.5% experienced Grade 4
neutropenia or thrombocytopenia in the first cycle, ...
More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
... (NCI Grades 3/4) lab abnormalities -- including
neutropenia (3.6%-48%), anemia (1%-42%), thrombocytopenia ... adverse reactions were thrombocytopenia (28%),
neutropenia (28%), elevated lipase (15%) and hyperglycemia ... adverse reactions were thrombocytopenia (37%),
neutropenia (37%), anemia (23%) and elevated lipase (17%). ...
Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkin's Lymphoma
... CHOP-R related toxicities included grade 3 to 4
neutropenia occurred
in 23 (39%) patients and grade 3 to 4 ... with Zevalin was
myelosuppression. Grade 3 to 4
neutropenia occurred in 28 (51%) of patients
with one incidence of febrile
neutropenia requiring hospitalization. Grade
3 to 4 ...
Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease
... (NCI Grades 3/4) lab
abnormalities--including
neutropenia (3.6%-48%), anemia (1%-42%),
thrombocytopenia ... included anemia
(17%), thrombocytopenia (17%),
neutropenia (8%) and increased creatinine
(8%).
In GIST, ... abnormalities (400 mg/day; 600
mg/day)--including
neutropenia (10%; 11%), anemia (3%; 9%),
thrombocytopenia ...
Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
... The
most commonly reported adverse events were
neutropenia and mouth sores.
"These preliminary results are ... Grade 2 and 3 mouth sores
and grade 3 and 4
neutropenia were seen. Among 11 patients evaluated ... arm, grade 2 and 3 mouth sores and grade 3 and
4
neutropenia were seen.
About breast cancer
Breast cancer ...
Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
... neutrophil count, hemoglobin level, or
neutropenia with fever) may require dose reduction, delay in ... or hemorrhage -- Sepsis occurring during
neutropenia has resulted in discontinuation of ... DOXIL vs VELCADE, respectively) included:
neutropenia (36% vs 22%), thrombocytopenia (33% vs ...
Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
... than or equal
to grade 3 toxicities included
neutropenia (11 patients) and
thrombocytopenia (16 ... Reversible
hematologic toxicities included
neutropenia grade 4 in 5 patients and grade
3 in 13 patients. ... occurred in 16 of 20
patients with grade 3-4
neutropenia reported in 11 of 20 patients. Four
patients ...
Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
... met the safety criterion for duration of
neutropenia (less than or equal to five days of severe neutropenia). In these trial conditions, severe
neutropenia typically lasts approximately seven days ... $4 billion in 2006.
About Neutropenia
neutropenia is a severe decrease in neutrophil cell counts in ...
Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting
... neutrophil count, hemoglobin level, or
neutropenia with fever) may require dose reduction, delay in ... or hemorrhage -- Sepsis occurring during
neutropenia has resulted in discontinuation of ... plus DOXIL vs VELCADE, respectively) included:
neutropenia (36% vs 22%), thrombocytopenia (33% vs 28%), ...
Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
... cisplatin and fluorouracil arm
(PF) had grade 3/4
neutropenia (76.9% vs. 52.5%), alopecia (11.6% vs. ... in
the Taxotere-based regimen included febrile
neutropenia (5.2%) and
neutropenic infection (13.9%). The ... Patients treated with TPF had more febrile
neutropenia (12% vs 7%),
neutropenic infection (12% vs 8%), ...
Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
... most common grade 3, 4 adverse event observed on the pixantrone arm was
neutropenia in 41.2% of patients versus 19.4% on the comparator arm. However, the incidence of grade 3, 4 febrile
neutropenia was only 7.4% versus 3.0% in the comparator arm. Grade 3, 4 infections ...
Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
... most common grade 3, 4 adverse event observed on the pixantrone arm was
neutropenia in 41.2% of patients versus 19.4% on the comparator arm. However, the incidence of grade 3, 4 febrile
neutropenia was only 7.4% versus 3.0% in the comparator arm. Grade 3, 4 infections ...
Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer
... reactions were stomatitis (44% for IC+CRT vs. 31% for CRT) and febrile
neutropenia (10% for IC+CRT vs. 1% for CRT). Other adverse events included
neutropenia and asthenia.
"These study results illustrate that this complex ...
Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
... Leukine data highlights include the following:
Chemotherapy-Induced
neutropenia
Budget impact analysis of sargramostim use in patients with chemotherapy-induced
neutropenia
Lead investigator: M. Duh, Analysis Group, Inc., Boston, MA
...
Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
...
With regard to hematologic toxicities, thrombocytopenia and
neutropenia were more frequent and severe with the FOLPI regimen compared with FOLFOX. However, only one episode of febrile
neutropenia and no bleeding complications have been observed to date. In addition, 83 ...
InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)
... by the investigator to be unrelated to ITMN-191. The other two were
neutropenia and indirect bilirubin elevation.
neutropenia occurred with a similar pattern, frequency and severity in the placebo and ...
Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer
... fatigue (50 percent), diarrhea (27 percent), nausea, anorexia, and
neutropenia (all 23 percent), vomiting and dizziness (18 percent). The most common Grade 3/4 toxicity was
neutropenia (23 percent) and was the only Grade 3/4 adverse event that occurred in ...
Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients
... (21%), cough and
insomnia (each 20%), rash (18%), arthralgia (17%),
neutropenia and dizziness
(excluding vertigo) (each 17%), pain in limb and abdominal ... with MP vs MP,
respectively, were thrombocytopenia (52% vs 47%),
neutropenia (49% vs 46%),
nausea (48% vs 28%), peripheral neuropathy (47% vs 5%), ...
New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
... with MP vs MP,
respectively, were thrombocytopenia (52% vs 47%),
neutropenia (49% vs 46%),
nausea (48% vs 28%), peripheral neuropathy (47% vs 5%), ... than or equal to Grade 4 toxicity, most commonly
thrombocytopenia (5%) and
neutropenia (3%). A total of 50% of patients
experienced serious adverse events (SAEs) ...
Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
... 3-5 adverse events, regardless of relation to
treatment, were febrile
neutropenia in 8 patients, and
neutropenia and
thrombocytopenia in 7 patients respectively. One patient died within ...
CellCept(R) and a Reduced Level of CNI Shows Trend Towards Preservation of Kidney Function Versus a Standard-Dose CNI
... pill and could theoretically reduce its effectiveness. -- Severe
neutropenia [absolute neutrophil count (ANC) cardiac, and up to 3.6% of ... Patients receiving CellCept should be monitored for neutropenia. If
neutropenia develops (ANC dosing with CellCept should be interrupted or the dose ...
Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
... pill and could theoretically reduce its effectiveness. -- Severe
neutropenia [absolute neutrophil count (ANC) 10cubed/microL] developed in up to ... Patients receiving CellCept should be monitored for neutropenia. If
neutropenia develops (ANC CellCept should be interrupted or the dose reduced, ...
New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data
... Oncology, Hospital Saint Antoine,
Paris, France.
In the MOSAIC trial,
neutropenia (decrease in the number of white blood
cells) was the most frequently reported side effect, affecting 78.9% of
patients.
neutropenia was complicated by fever or infection in only 1.8% of
cases. Peripheral ...
Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market
... for the European market. The market launch is planned
for early 2010.
neutropenia - a condition whereby the concentration of neutrophils (a
type of white ... colony stimulating factor (G-CSF) is a human
protein that can reverse
neutropenia by initiating the production of
neutrophils. Recombinant forms of the ...
Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
... or refractory anemia with ringed sideroblasts (RARS)
if accompanied by
neutropenia or thrombocytopenia or requiring
transfusions; refractory anemia with ... hypokalemia (31.3%).
Because treatment with Vidaza is associated with
neutropenia and
thrombocytopenia, complete blood counts should be performed as needed ...
MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule
... or refractory anemia with ringed sideroblasts (RARS)
if accompanied by
neutropenia or thrombocytopenia or requiring
transfusions; refractory anemia with ... hypokalemia (31.3%).
Because treatment with Vidaza is associated with
neutropenia and
thrombocytopenia, complete blood counts should be performed as needed ...
Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
... trials to have a higher risk
of developing myelosuppression. Grade 3/4
neutropenia (lab and AE combined)
occurred in eight percent and Grade 3/4 ... treated with temozolomide. In refractory anaplastic astrocytoma,
Grade 3/4
neutropenia occurred in 14 percent and Grade 3/4 thrombocytopenia
occurred in 19 ...
Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
... and fluorouracil
(PF). Patients treated with TPF had more febrile
neutropenia (12% vs 7%),
neutropenic infection (12% vs 8%), and grade 3/4
neutropenia (84% vs. 56%),
dizziness (4% vs. 2%), alopecia (4% vs 1%) and diarrhea (7% ...
Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
... leukopenia (16%); anemia (6%); thrombocytopenia (5%); infection
without
neutropenia (2%); fatigue (17%); thrombosis/embolism (6%); nausea
(12%); vomiting ... (72%); chest pain (38%);
neuropathy/sensory (29%); infection without
neutropenia (23%); and rash
(17%). See complete Warnings, Precautions, Adverse ...
Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
... Anaemia, leucopenia, thrombocytopenia,
neutropenia. Common: Febrile
neutropenia and infection without neutropenia.
Uncommon: Pancytopenia. ... associated with an
increased incidence of infections. Fatigue and febrile
neutropenia also
occur more frequently with this combination. Administration site ...
OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer
... None of the patients in cohort one had an initial dose-limiting toxicity (IDLT) with two cycles of therapy. There was one IDLT of infection with
neutropenia in cohort two. Aside from grade 3 fatigue in two patients, there were no grade 3 or greater nonhematologic toxicities. A median of 4.5 cycles was ...
R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
... Had a Dose Reduction 2 3% 21 14%
---------------------- --- --- --- ---
neutropenia (ANC less than 1500) 0 0% 3 2%
-------------------------------- --- --- --- ---
Diarrhea, ...
FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)
... a child while receiving treatment with Dacogen and for two months afterwards. The most commonly occurring adverse reactions with Dacogen include
neutropenia (90 percent), thrombocytopenia (89 percent), anemia (82 percent), pyrexia (53 percent), fatigue (48 percent), nausea (42 percent), cough (40 ...
Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial
... was well tolerated. The most commonly reported adverse events (grade 3 or 4; >10% patients) in this heavily pretreated population included anemia,
neutropenia and thrombocytopenia(1).
About non-Hodgkin's lymphoma and Hodgkin's disease
Non-Hodgkin's lymphoma and Hodgkin's disease manifest in the ...
Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
... regimens produced encouragingly high rates of overall response (58-74%) including high rates of complete responses (37-57%). As previously reported,
neutropenia was the dose limiting toxicity when used as a single agent.
"In both preclinical and early clinical studies pixantrone exhibited lower cardiac ...